What does the Pharma CRO landscape look like in Europe?

Consolidation has progressed across both the discovery & preclinical and clinical CRO segments in Europe, although the dynamics differ across the segments. In Europe’s discovery and preclinical CRO segment, deals are more often capability-led bolt-ons that add specialist scientific, regulatory or modality expertise. In contrast, consolidation in the clinical segment is centred around the development of scaled, technology-enabled end-to-end platforms. As pharmaceutical companies streamline vendor lists and digital transformation raises the need for integrated delivery, mid-tier CROs get increasingly squeezed out. In addition, two structural shifts are reshaping the market. First, AI is increasingly used to accelerate drug discovery and preclinical research while reducing costs. At the same time, clinical outsourcing is shifting from traditional full-service contracts (FSO) toward more modular functional service provision (FSP) models tailored to specific needs, alongside growing adoption of hybrid decentralised trial execution driven by demand for greater patient convenience and more efficient monitoring.